Airsculpt Technologies Inc (AIRS)vsNovartis AG ADR (NVS)
AIRS
Airsculpt Technologies Inc
$5.11
-10.51%
HEALTHCARE · Cap: $382.36M
NVS
Novartis AG ADR
$148.38
-0.55%
HEALTHCARE · Cap: $273.77B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 37163% more annual revenue ($56.58B vs $151.84M). NVS leads profitability with a 23.9% profit margin vs -7.4%. NVS earns a higher WallStSmart Score of 49/100 (D+).
AIRS
Avoid34
out of 100
Grade: F
NVS
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+11.7%
Fair Value
$2.40
Current Price
$5.11
$2.71 discount
Margin of Safety
-62.1%
Fair Value
$91.39
Current Price
$148.38
$56.99 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 200.0% YoY
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
0.0% revenue growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -11.2% — below average capital efficiency
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : AIRS
The strongest argument for AIRS centers on EPS Growth.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : AIRS
The primary concerns for AIRS are Revenue Growth, Market Cap, Piotroski F-Score.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Key Dynamics to Monitor
AIRS profiles as a turnaround stock while NVS is a declining play — different risk/reward profiles.
AIRS carries more volatility with a beta of 2.02 — expect wider price swings.
AIRS is growing revenue faster at 0.0% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (49/100 vs 34/100), backed by strong 23.9% margins. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Airsculpt Technologies Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Airsculpt Technologies Inc (AIRS) is a pioneering company in the aesthetic medical technology sector, renowned for its innovative AirSculpt® procedure that delivers minimally invasive body contouring with a strong commitment to patient safety and comfort. The company is strategically expanding its network of licensed practitioners, supported by a robust focus on technological advancements, which positions Airsculpt favorably within the rapidly growing non-invasive cosmetic treatment market. As consumer demand for aesthetic solutions continues to rise globally, Airsculpt is well-positioned to enhance its market share and diversify its service offerings, aiming to achieve substantial growth and sustainable value for its investors.
Visit Website →Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other MEDICAL CARE FACILITIES Stocks
Want to dig deeper into these stocks?